Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129284 | 1.00 | HDAC1 (0.59) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL4486001 | 1.00 | HDAC1 (0.59) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL133000 | 1.00 | HDAC1 (0.59) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL130489 | 0.98 | CYP1A2 (0.61) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL15352037 | 0.92 | CYP1A2 (0.54) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL131604 | 0.92 | CYP1A2 (0.62) | HDAC1HDAC8CYP1A2SIGMAR1CYP2A6 | |
| SCHEMBL30418043 | 0.90 | SIGMAR1 (0.66) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL30418669 | 0.88 | SIGMAR1 (0.68) | HDAC1HDAC8CYP1A2SIGMAR1NAAA | |
| SCHEMBL16414518 | 0.86 | CYP1A2 (0.56) | HDAC1HDAC8CYP1A2SIGMAR1CYP2A6 | |
| SCHEMBL131160 | 0.84 | CYP1A2 (0.56) | HDAC1HDAC8CYP1A2SIGMAR1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-06-04 | — | — | US | disclosed |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION | 2015-05-07 | — | — | US | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-8946262-B2 | Methods of preventing and treating gastrointestinal dysfunction | ADOLOR CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8895560-B2 | Opioid antagonists | ADOLOR CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-10-09 | — | — | US | disclosed |
| US-20140186951-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-6852713-B2 | Lactam derivatives and methods of their use | ADOLOR CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2005004796-A2 | SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004112704-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040254218-A1 | Substituted piperidine compounds and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CALIXA THERAPEUTICS, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004093796-A2 | LACTAM DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040209857-A1 | Lactam derivatives and methods of their use | ADOLOR CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004082623-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS | ADOLOR CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186135-A1 | Substituted piperidine compounds | CUBIST PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254218-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRK1, OPRD1 | HDAC1 1344/4885HDAC8 1055/4885CYP1A2 332/4885 |
| US-20040186135-A1 | Substituted piperidine compounds | OPRK1, OPRD1, OPRM1 | HDAC1 913/4885HDAC8 899/4885CYP1A2 558/4885 |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CYP2E1, CYP2D6, CYP3A43 | HDAC1 478/4885HDAC8 1666/4885CYP1A2 11/4885 |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | HDAC1 475/4885HDAC8 2026/4885CYP1A2 18/4885 |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | VIP, FABP2, SI | HDAC1 853/4885HDAC8 1171/4885CYP1A2 530/4885 |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | HDAC1 4207/4885HDAC8 4396/4885CYP1A2 157/4885 |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRD1 | HDAC1 2191/4885HDAC8 3507/4885CYP1A2 102/4885 |
| US-20040209857-A1 | Lactam derivatives and methods of their use | MRPL21, SI, PEPD | HDAC1 1616/4885HDAC8 2799/4885CYP1A2 100/4885 |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | HDAC1 286/4885HDAC8 217/4885CYP1A2 273/4885 |
| US-20140186951-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | HDAC1 1116/4885HDAC8 1836/4885CYP1A2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.